Litcius/Paper detail

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

Sylvie Lorenzen, Peter Thuss‐Patience, Claudia Pauligk, Eray Gökkurt, Thomas J. Ettrich, Florian Lordick, Michael Stahl, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Axel Hinke, Thorsten Oliver Goetze, S. Al-Batran

2022European Journal of Cancer56 citationsDOI

Topics & Concepts

RamucirumabFOLFIRIMedicineDocetaxelInternal medicineClinical endpointHazard ratioPopulationMetastatic breast cancerPhases of clinical researchPaclitaxelOncologyChemotherapyGastroenterologySurgeryCancerConfidence intervalRandomized controlled trialBreast cancerIrinotecanColorectal cancerEnvironmental healthGastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentColorectal Cancer Treatments and Studies
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO | Litcius